Search

Your search keyword '"Tennekoon, Gihan"' showing total 322 results

Search Constraints

Start Over You searched for: Author "Tennekoon, Gihan" Remove constraint Author: "Tennekoon, Gihan"
322 results on '"Tennekoon, Gihan"'

Search Results

2. Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

Catalog

Books, media, physical & digital resources

3. MR biomarkers predict clinical function in Duchenne muscular dystrophy

4. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

6. Modeling disease trajectory in Duchenne muscular dystrophy

8. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

9. Two-Year Longitudinal Changes in Lower Limb Strength and Its Relation to Loss in Function in a Large Cohort of Patients With Duchenne Muscular Dystrophy

10. Quantitative Evaluation of Lower Extremity Joint Contractures in Spinal Muscular Atrophy: Implications for Motor Function

12. Childhood Multiple Sclerosis: A Review

13. Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance

14. Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and Ambulatory Function

15. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort

16. Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy

17. SPINAL MUSCULAR ATROPHY FUNCTIONAL COMPOSITE SCORE: A FUNCTIONAL MEASURE IN SPINAL MUSCULAR ATROPHY

18. Association of a Novel ACTA1 Mutation With a Dominant Progressive Scapuloperoneal Myopathy in an Extended Family

25. Psychometric properties of the PEDI-CAT for children and youth with spinal muscular atrophy

26. MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated serum creatine kinase

30. Walking activity in a large cohort of boys with Duchenne muscular dystrophy

31. Upper and Lower Extremities in Duchenne Muscular Dystrophy Evaluated with Quantitative MRI and Proton MR Spectroscopy in a Multicenter Cohort

32. One-Time Intrathecal (IT) Administration of AVXS-101 IT Gene-Replacement Therapy for Spinal Muscular Atrophy: Phase 1 Study (STRONG) (2493)

34. Myelin Po-protein, more than just a structural protein?

36. MLIP causes recessive myopathy with rhabdomyolysis, myalgia and baseline elevated  serum creatine kinase.

37. Dominant collagen XII mutations cause a distal myopathy

38. Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy (S51.006)

39. Phase 1 Study of Intrathecal Administration of AVXS-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 2 (SMA2) (STRONG) (P1.6-059)

41. Dominant collagen XII mutations cause a distal myopathy

43. Walking activity in a large cohort of boys with Duchenne muscular dystrophy.

44. Nusinersen versus sham control in later-onset spinal muscular atrophy

45. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history

46. Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy

47. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history

48. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression

49. Evaluator Training and Reliability for SMA Global Nusinersen Trials1

50. MoveDMD®: Positive Effects of Edasalonexent, an NF-κB Inhibitor, in 4 to 7-Year Old Patients with Duchenne Muscular Dystrophy in Phase 2 Study with an Open-Label Extension (S29.006)